Independence of growth factor induced plasminogen activator inhibitor type-1 (PAI-1) expression from the 4G/5G polymorphism of the PAI-1 gene

Summary

Increased PAI-1 expression has been implicated in accelerating atherogenesis. Increases under some conditions are modulated by growth factors. Genetic factors such as the 4G/5G poly-morphism in the promoter of the PAI-1 gene play a role under certain circumstances. The present study was designed to delineate for the first time interactions between growth factors and the 4G/5G polymorphism with respect to PAI-1 expression in human arterial smooth muscle cells (HASMC).

HASMC were genotyped and exposed to growth factors. PAI-1 gene and protein expression were induced consistently by TGF-β (up to 4.0-fold), PDGF (2.1-fold),TNF-α (1.7-fold), and thrombin (2.3-fold). Results were similar regardless of which genotype (4G/4G [n=9], 4G/5G [n=13], and 5G/5G [n=7]) was present.

The induction of increased PAI-1 expression in human arterial smooth muscle cells by growth factors implicated in accelerated atherogenesis is independent of the PAI-1 4G/5G polymorphism. Accordingly, modulation of PAI-1 expression is likely to be influenced predominantly by environmental factors acting on, rather than genetic factors intrinsic to the PAI-1 promoter.

Keywords

Growth factors - TGF-β - genotype - endogenous fibrinolysis - PAI-1

• References

• 1 Nordt TK, Peter K, Ruef J, Kübler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999; 82 (suppl.) 14-8.
• 2 Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266: 9419-27.
• 3 Bochaton-Piallat ML, Gabbiani G, Pepper MS. Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines. Circ Res 1998; 82: 1086-93.
• 4 Sperti G, van Leeuwen R, Maseri A, Kluft C. Platelet-derived growth factor increases plasminogen activator inhibitor-1 activity and mRNA in rat cultured vascular smooth muscle. Ann N Y Acad Sci 1992; 667: 167-80.
• 5 Lau HK. Regulation of proteolytic enzymes and inhibitors in two smooth muscle cell phenotypes. Cardiovasc Res 1999; 43: 1049-59.
• 6 Lee L, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P, Lark MW, Lee RT. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res 1996; 78: 44-9.
• 7 Noda-Heiny H, Fujii S, Sobel BE. Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by throm-bin. Circ Res 1993; 72: 36-43.
• 8 Wojta J, Gallicchio M, Zoellner H, Hufnagl P, Last K, Filonzi EL, Binder BR, Hamilton JA, McGrath K. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 1993; 70: 469-74.
• 9 Cockell KA, Ren S, Sun J, Angel A, Shen GX. Effect of thrombin on release of plasminogen activator inhibitor-1 from cultured primate arterial smooth muscle cells. Thromb Res 1995; 77: 119-31.
• 10 Wang W, Chen HJ, Schwartz A, Cannon PJ, Rabbani LE. T cell lymphokines modulate bFGF-induced smooth muscle cell fibrinoly-sis and migration. Am J Physiol 1997; 272: C392-8.
• 11 Louwrens HD, Kwaan HC, Pearce WH, Yao JST, Verrusio E. Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture.. Eur J Endovasc Surg 1995; 10: 289-93.
• 12 van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 3628
• 13 Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and-2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-62.
• 14 Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18: 1771-9.
• 15 Coats SR, Covington JW, Su M, Pabon-Pena LM, Eren M, Hao Q, Vaughan DE. SSeCKS gene expression in vascular smooth muscle cells: regulation by angiotensin II and a potential role in the regulation of PAI-1 gene expression. J Mol Cell Cardiol 2000; 32: 220719
• 16 Chen HC, Bouchie JL, Perez AS, Clermont AC, Izumo S, Hampe J, Feener EP. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol 2000; 20: 2297-302.
• 17 Bouchie JL, Chen HC, Carney R, Bagot JC, Wilden PA, Feener EP. P2Y receptor regulation of PAI-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 866-73.
• 18 Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angioten-sin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-44.
• 19 Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymorphisms: Impact on atherogenesis. Thromb Res 2001; 103: S1-S5.
• 19a McCormack LJ, Semple JI, Stickland MH, Barrett JH, Grant PJ. The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells. Thromb Res 1998; 92: 199-206.
• 20 Nordt TK, Peter K, Bode C, Sobel BE. Differential regulation by troglitazone of plasmino-gen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocr Metab 2000; 85: 1563-8.
• 21 Nordt TK, Kornas K, Peter K, Fujii S, Sobel BE, Kübler W, Bode C. Attenuation by gem-fibrozil of expression of plasminogen activator inhibitor type-1 induced by insulin and its precursors. Circulation 1997; 95: 677-83.
• 22 Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-7.
• 23 Margaglione M, Grandone E, Cappucci G. et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Hae-most 1997; 77: 605-6.
• 24 Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
• 25 Thögersen AM, Jansson JH, Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
• 26 Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80: 1029-30.
• 27 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
• 28 Eriksson P, Nilsson L, Karpe F, Hamsten A. Very low-density lipoprotein response element in the promoter region of the human plasmino-gen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18: 20-6.
• 29 Ahn JD, Morishita R, Kaneda Y. et al. Transcription factor decoy for activator protein-1 (AP-1) inhibits high glucose-and angiotensin II-induced type 1 plasminogen activator inhibitor (PAI-1) gene expression in cultured human vascular smooth muscle cells. Diabetologia 2001; 44: 713-20.
• 30 Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: A reconcilable paradox. Circulation 1999; 99: 2496-8.